Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

723 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination.
Alidjinou EK, Demaret J, Corroyer-Simovic B, Vuotto F, Miczek S, Labreuche J, Goffard A, Trauet J, Lupau D, Dendooven A, Huvent-Grelle D, Podvin J, Dreuil D, Faure K, Deplanque D, Bocket L, Duhamel A, Sobaszek A, Hober D, Hisbergues M, Puisieux F, Autran B, Yazdanpanah Y, Labalette M, Lefèvre G. Alidjinou EK, et al. Among authors: yazdanpanah y. Clin Microbiol Infect. 2023 Feb;29(2):258.e1-258.e4. doi: 10.1016/j.cmi.2022.10.014. Epub 2022 Oct 17. Clin Microbiol Infect. 2023. PMID: 36257549 Free PMC article.
Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
Bocket L, Peytavin G, Alidjinou EK, Ajana F, Choisy P, Lê M, Charpentier C, Descamps D, Yazdanpanah Y, Katlama C, Simon A, Calvez V, Marcelin AG, Soulie C. Bocket L, et al. Among authors: yazdanpanah y. J Antimicrob Chemother. 2016 Sep;71(9):2651-3. doi: 10.1093/jac/dkw167. Epub 2016 May 27. J Antimicrob Chemother. 2016. PMID: 27234463
Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives.
Hingrat QL, Visseaux B, Laouenan C, Tubiana S, Bouadma L, Yazdanpanah Y, Duval X, Burdet C, Ichou H, Damond F, Bertine M, Benmalek N, Choquet C, Timsit JF, Ghosn J, Charpentier C, Descamps D, Houhou-Fidouh N; French COVID cohort management committee, CoV-CONTACT study group; members of the French-COVID cohort study group (by alphabetical order); member of the CoV-CONTACT study group. Principal investigator; Steering Committee; CoV-CONTACT Clinical Centers; Coordination and statistical analyses; Virological Lab; Biological Center; Partners; Sponsor; Genetic. Hingrat QL, et al. Among authors: yazdanpanah y. Clin Microbiol Infect. 2020 Dec 8;27(5):789.e1-5. doi: 10.1016/j.cmi.2020.11.025. Online ahead of print. Clin Microbiol Infect. 2020. PMID: 33307227 Free PMC article.
High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort.
Tubiana S, Burdet C, Houhou N, Thy M, Manchon P, Blanquart F, Charpentier C, Guedj J, Alavoine L, Behillil S, Leclercq A, Lucet JC, Yazdanpanah Y, Attia M, Demeret C, Rose T, Bielicki JA, Bruijning-Verhagen P, Goossens H, Descamps D, van der Werf S, Lina B, Duval X; CoVCONTACT study group; Principal investigator; Sponsor: Inserm. Tubiana S, et al. Among authors: yazdanpanah y. J Infect. 2021 May;82(5):186-230. doi: 10.1016/j.jinf.2021.01.026. Epub 2021 Feb 3. J Infect. 2021. PMID: 33545165 Free PMC article. No abstract available.
Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019.
Betton M, Livrozet M, Planas D, Fayol A, Monel B, Védie B, Bruel T, Tartour E, Robillard N, Manuguerra JC, Blanchard A, Ghosn J, Visseaux B, Péré H, Lebeaux D, Schwartz O, Veyer D, Hulot JS; French COVID Cohort Study Group. Betton M, et al. Clin Infect Dis. 2021 Sep 15;73(6):e1337-e1344. doi: 10.1093/cid/ciab308. Clin Infect Dis. 2021. PMID: 33851216 Free PMC article.
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy study group. Ader F, et al. Among authors: yazdanpanah y. Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26. Clin Microbiol Infect. 2021. PMID: 34048876 Free PMC article. Clinical Trial.
723 results